Syren Biotech (688163.SH) announced semi-annual results, with net profit of 35.65 million yuan to mother, an increase of 8.11% over the previous year

According to Zhitong Finance App News, Salen Biotech (688163.SH) disclosed its 2026 semi-annual report. During the reporting period, the company achieved operating income of 104 million yuan, up 3.36% year on year; net profit attributable to shareholders of listed companies was 35.65 million yuan, up 8.11% year on year; after deducting non-net profit of 31.08 million yuan, up 8.96% year on year; basic income per share was 0.33 yuan; and plans to distribute a cash dividend of 1.2 yuan (tax included) for every 10 shares.

Revenue increased by 3.36% over the same period last year, mainly due to the year-on-year increase in revenue driven by the increase in sales volume of anti-snake venom serum products in the current period. Net profit attributable to shareholders of listed companies increased 8.11% over the same period of the previous year, mainly due to an increase in operating income and a decrease in sales expenses during the reporting period.